{
    "clinical_study": {
        "@rank": "90798", 
        "arm_group": [
            {
                "arm_group_label": "Observational", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients on the Observational arm are currently being treated with a proton pump inhibitor (PPIs) such as Omeprazole.  They will receive standard of care chemotherapy.  Standard treatment is the choice of the treating physician and may include Carboplatin in combination with either 5FU, Paclitaxel, or Pemetrexed."
            }, 
            {
                "arm_group_label": "Standard Chemo + Placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients on the Standard Chemo and Placebo arm are not currently being treated with a proton pump inhibitor (PPI).  They will be randomized to receive placebo along with standard of care chemotherapy.  Standard treatment is the choice of the treating physician and may include Carboplatin in combination with either 5FU, Paclitaxel, or Pemetrexed."
            }, 
            {
                "arm_group_label": "Standard Chemo + Omeprazole", 
                "arm_group_type": "Experimental", 
                "description": "Patients on the Standard Chemo and Placebo arm are not currently being treated with a proton pump inhibitor (PPI).  They will be randomized to receive Omeprazole along with standard of care chemotherapy.  Standard treatment is the choice of the treating physician and may include Carboplatin in combination with either 5FU, Paclitaxel, or Pemetrexed."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if the addition of proton pump inhibitors (PPIs)\n      to standard chemotherapy can improve progression free survival in patients with head and\n      neck cancer."
        }, 
        "brief_title": "A Phase II Trial of Proton Pump Inhibitors With Chemotherapy in Patients With Metastatic Head and Neck Cancer", 
        "condition": "Cancer of Head and Neck", 
        "condition_browse": {
            "mesh_term": "Head and Neck Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and non-pregnant, non-lactating females at least 18 years old.\n\n          -  Histologically or cytologically confirmed diagnosis of SCCHN (Squamous Cell Carcinoma\n             of the Head and Neck).\n\n          -  Stage IVC (metastatic) or advanced, locally recurrent SCCHN not amenable to curative\n             surgery or radiotherapy.\n\n          -  Measurable disease as defined by RECIST (Response Evaluation Criteria in Solid\n             Tumors) vs 1.1 (Appendix 1).\n\n             a. If the only site of measurable disease for this study is within a prior field of\n             irradiation, then the sum of the longest diameters (SLD) of that lesion must have\n             increased by at least 20% from the prior treatment nadir.\n\n          -  ECOG Performance status (measure of health and general well being on a scale of 0 to\n             5 where 0 represents perfect health) < 1 (Appendix 2).\n\n          -  Expected survival of at least 3 months.\n\n          -  Adequate liver and renal function that is defined as Calculated creatinine clearance\n             of <30ml/min (by Jelliffe calculator) AST (aspartate aminotransferase)/ALT (alanine\n             aminotransferase) < 2.5 X ULN (unless there are hepatic metastasis, in which case\n             AST/ALT within 5 X ULN) Total Bilirubin < 1.5 X ULN (Appendix 5).\n\n          -  Ability to understand and willingness to sign an informed consent form.\n\n          -  Willingness and ability to comply with study procedures and follow up.\n\n          -  There is no restriction on number of prior therapies as long as the patient is deemed\n             a candidate for palliative chemotherapy with one of the standard chemotherapy\n             regimens.\n\n          -  Willingness to use contraception by a method that is deemed effective by the\n             Investigator by both male and female patients of childbearing potential and their\n             partners throughout the treatment period and for at least 30 days following the last\n             cycle of chemotherapy (post menopausal women must have been amenorrheal for at-least\n             12 months to be considered of non-childbearing potential).\n\n        Exclusion Criteria:\n\n          -  Comorbidities precluding treatment with combination chemotherapy or per investigator\n             discretion.\n\n          -  Pregnancy or lactation.\n\n          -  Medical or psychiatric illness that may compromise the patient's ability to tolerate\n             the treatment or comply with the study requirements.\n\n          -  Patients with another active cancer or history of another cancer in the last 3 years\n             except those treated with curative intent such as skin cancer (other than melanoma),\n             in situ breast or in situ cervical cancer or those treated with curative intent for\n             any other cancer with no evidence of disease for 2 years.\n\n          -  Allergy to PPI or inability to tolerate PPI.\n\n          -  Patients residing in prison.\n\n          -  Any investigational drug dose within 28 days of planned start of trial.\n\n          -  Any concurrent standard therapy intended to treat SCCHN.\n\n          -  Any symptomatic infection (bacterial, fungal or viral) as per the investigator\n             discretion.\n\n          -  Patients with uncontrolled CNS (Central Nervous System) metastases are excluded.\n             Patients with known, previously treated CNS metastases are eligible if they are\n             neurologically stable as per the investigating physician's clinical assessment.\n\n          -  Any other condition or circumstance that would, in the opinion of the Investigator,\n             make the patient unsuitable for participation in the study.\n\n          -  Patients on Rilpivirine, Atazanavir, Indinavir and Nelfinavir will not be eligible\n             for participation in study because of the significant drug interaction unless the\n             patient can be switched to a different antiviral medication prior to study\n             enrollment.\n\n          -  Omeprazole can increase the serum concentration of methotrexate, clorazepate and\n             citalopram increasing the risk of adverse effects.\n\n          -  Omeprazole may result in reduction in clinical efficacy of clopidogrel and increased\n             risk for thrombosis.\n\n          -  Omeprazole when co-administered with dasatinib, bosutinib, ponatinib, erlotinib,\n             dabrafenib and vismodegib reduces the systemic exposure to these drugs, therefore\n             patients on these drugs should not be enrolled in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02013453", 
            "org_study_id": "UMCC 2013.046", 
            "secondary_id": "HUM00074951"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Observational", 
                    "Standard Chemo + Omeprazole"
                ], 
                "description": "40mg of Omeprazole will be administered daily by mouth.", 
                "intervention_name": "Omeprazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Observational", 
                    "Standard Chemo + Placebo", 
                    "Standard Chemo + Omeprazole"
                ], 
                "description": "Carboplatin will be administered over 30 minutes by continuous infusion.", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Observational", 
                    "Standard Chemo + Placebo", 
                    "Standard Chemo + Omeprazole"
                ], 
                "description": "Administered by infusion.", 
                "intervention_name": "5FU", 
                "intervention_type": "Drug", 
                "other_name": "5-Fluorouracil, Efudex"
            }, 
            {
                "arm_group_label": [
                    "Observational", 
                    "Standard Chemo + Placebo", 
                    "Standard Chemo + Omeprazole"
                ], 
                "description": "Administered by infusion.", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Observational", 
                    "Standard Chemo + Placebo", 
                    "Standard Chemo + Omeprazole"
                ], 
                "description": "Administered by infusion.", 
                "intervention_name": "Pemetrexed", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Pemetrexed", 
                "Carboplatin", 
                "Paclitaxel", 
                "Omeprazole", 
                "Proton Pump Inhibitors"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 11, 2013", 
        "location": {
            "contact": {
                "email": "fworden@umich.edu", 
                "last_name": "Francis Worden, M.D.", 
                "phone": "734-936-0453"
            }, 
            "facility": {
                "address": {
                    "city": "Ann Arbor", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "48109"
                }, 
                "name": "University of Michigan Hospital"
            }, 
            "investigator": {
                "last_name": "Francis Worden, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase II Randomized Trial Evaluating the Use of Proton Pump Inhibitors (PPIs) in Conjunction With Chemotherapy, in Patients With Recurrent Unresectable or Metastatic Cancers of the Head and Neck", 
        "overall_contact": {
            "email": "fworden@umich.edu", 
            "last_name": "Francis Worden, M.D.", 
            "phone": "734-936-0453"
        }, 
        "overall_official": {
            "affiliation": "University of Michigan Cancer Center", 
            "last_name": "Francis Worden, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary aim, progression-free survival, will be defined from start of treatment to date of first progression and will be tested using a Cox proportional hazard regression model with treatment arm as the only predictor.", 
            "measure": "Time to progression", 
            "safety_issue": "No", 
            "time_frame": "6 months post treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02013453"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Michigan Cancer Center", 
            "investigator_full_name": "Francis (Frank) Worden", 
            "investigator_title": "Associate Professor of Internal Medicine, Medical School", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall survival be evaluated with Cox models and will be defined from the first date of treatment to date of death.", 
                "measure": "Median overall survival", 
                "safety_issue": "No", 
                "time_frame": "6 months post treatment"
            }, 
            {
                "description": "Estimate the proportion of patients with a complete response (CR), partial response (PR), objective response (CR+PR) and clinical benefit (CR+PR+Stable disease) and compare responses between the group receiving proton pump inhibitors (PPI) and the group not receiving PPIs.", 
                "measure": "Proportion of patients that experience a response to treatment", 
                "safety_issue": "No", 
                "time_frame": "6 months post treatment"
            }
        ], 
        "source": "University of Michigan Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Michigan Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}